GE Healthcare eyes $300 million opportunity with Flyrcado adoption in US, Evercore says

GE Healthcare GEHC.O says Cardiovascular Associates of America (CVAUSA), the largest network of private cardiology groups in the U.S., plans to broaden adoption of co's Flyrcado injection

Flyrcado is a type of medical dye used during a heart scan to check how well the blood is flowing

The deal with CVAUSA could lead to annualized revenue opportunity over time worth more than $300 mln- Evercore ISI

CVAUSA says it plans to use Flyrcado across about 25 sites

"While the pace of adoption across the 25 sites will determine time for GEHC to hit the peak >$300M revs, we think the economic incentives & image quality make a strong case for quicker adoption cycle"- Evercore

Up to last close, stock down 6.4% YTD